Home » Entries posted by pharmanewsdaily
Entries posted by pharmanewsdaily
AstraZeneca resumes AZD1222 Covid-19 vaccine trials after brief pause

AstraZeneca resumes AZD1222 Covid-19 vaccine trials after brief pause

AstraZeneca said that clinical trials for the AZD1222 Covid-19 vaccine candidate, have resumed in various parts of the world after regulators across the US, UK, Brazil, Japan, and South Africa confirmed that it was safe to continue them. The US Food and Drug Administration (FDA) has authorized the restart of AZD1222 clinical trials in the […]

Covid-19 mRNA vaccine : Precision Nanosystems gets funding boost from Canadian govt

Precision Nanosystems (PNI) has received a funding boost of up to CAD 18.2 million from the Canadian government to develop a mRNA vaccine for Covid-19. The funding from Canada’s Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) will help the Vancouver-based biotech company to move its Covid-19 mRNA vaccine candidate to clinical trials. […]

Continue reading …
Gilead Sciences wraps up $21bn acquisition of Immunomedics

Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has now become a fully-owned subsidiary of Gilead Sciences. The common stock of Immunomedics will be delisted from the Nasdaq Global Market. Immunomedics, which has been acquired for $88 per share […]

Continue reading …
Gilead Sciences bags Remdesivir FDA approval for Covid-19 treatment

Remdesivir FDA approval : Gilead Sciences, a California-based biopharma company, has bagged approval from the US Food and Drug Administration (FDA) for its antiviral drug Veklury (remdesivir) for Covid-19 treatment in patients requiring hospitalization. This makes remdesivir the first approved treatment for coronavirus in the US. Remdesivir FDA approved indication : Veklury has been approved […]

Continue reading …
VelosBio begins phase 2 trial of VLS-101 in solid tumors

VelosBio, a San Diego-based biopharma company, said that it has dosed the first patient in a phase 2 clinical trial of its investigational antibody-drug conjugate (ADC) VLS-101 in patients having solid tumors. VLS-101, which is the company’s lead product candidate, targets a cell-surface protein called ROR1. Expressed during embryofetal development, ROR1 is however not seen […]

Continue reading …
Endo International to acquire BioSpecifics Technologies for $658m

Endo International has agreed to acquire BioSpecifics Technologies, a New York-based commercial-stage biopharma company, for $88.5 per share, or an estimated enterprise value of around $658 million. The Irish pharma company and BioSpecifics Technologies have been in a strategic partnership since 2004. BioSpecifics Technologies had developing a form of injectable collagenase clostridium histolyticum (CCH), which […]

Continue reading …
Bracco Diagnostics gets FDA nod for CardioGen-82 infusion system

Bracco Diagnostics, the US subsidiary of Italian diagnostic imaging company Bracco Imaging, has secured approval from the US Food and Drug Administration (FDA) for its new CardioGen-82 infusion system. According to Bracco Diagnostics, CardioGen-82 infusion system is used for improving automation, efficiency, and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). CARDIOGEN-82 […]

Continue reading …
Lilly to acquire SARM1 inhibitor developer Disarm Therapeutics

Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]

Continue reading …
Oxford develops rapid diagnostic test to detect Covid-19 within 5mins

Oxford University claimed that scientists from its Physics department have developed an extremely rapid diagnostic test for Covid-19. The rapid diagnostic test can detect and identify viruses within five minutes, said the UK-based university. The method can be used to differentiate the SARS-CoV-2 virus from negative clinical samples and also from other common respiratory pathogens […]

Continue reading …
Regeneron bags Inmazeb FDA approval for treatment of Ebola

Inmazeb FDA approval : Regeneron Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its antibody cocktail Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of Zaire ebolavirus (Ebola virus). Formerly known as REGN-EB3, Inmazeb is now the first drug regimen to get FDA approval for Ebola treatment, covering adult and […]

Continue reading …
Page 1 of 134123Next ›Last »